This clinical stage biopharmaceutical company has seen no estimate revision in the last 30 days. The Zacks Consensus Estimate hasn’t been in trend either. Yesterday’s rally is encouraging though, so make sure to keep a close watch on this firm in the near future.
Geron currently holds a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.
Investors interested in the broader medical sector may consider other well-placed stocks like ANI Pharmaceuticals, Inc. (ANIP), Actelion Ltd. (ALIOF) and Agenus Inc. (AGEN). All the three stocks sport a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
To read this article on Zacks.com click here.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
Be the first to comment